PFIZER Business Summary

Pfizer Inc. operates as a research-based global biopharmaceutical company, generating revenue through the discovery, manufacture, and wholesale distribution of innovative medicines and vaccines. Its business is organized into three primary segments: Global Biopharmaceuticals (Biopharma), which encompasses its core therapeutic areas; Pfizer CentreOne (PC1), a global contract manufacturing organization; and Pfizer Ignite, which provides strategic R&D services to biotech partners. Following the $43 billion acquisition of Seagen and the strategic integration of Metsera's obesity pipeline, Pfizer has pivoted its commercial focus toward high-growth areas including antibody-drug conjugates (ADCs) in oncology, mRNA-based vaccines, and metabolic health. The company competes directly with Johnson & Johnson, Merck & Co., Eli Lilly, and Novartis. While Pfizer is currently navigating a post-pandemic transition and significant patent expirations, it maintains a dominant market position as a global leader in oncology and vaccine development, supported by a catalyst-rich pipeline of over 100 clinical candidates. Founded in 1849 by cousins Charles Pfizer and Charles Erhart, the company is led by Chairman and CEO Dr. Albert Bourla, a 30-year veteran of the firm who oversaw its transformation into a pure-play biopharma entity. The executive team includes David Denton as Chief Financial Officer, who brings extensive retail and healthcare experience from previous roles at Lowe’s and CVS Health, and Dr. Chris Boshoff, who was elevated to Chief Scientific Officer and President of R&D in early 2025 to lead the company’s oncology-centric innovation strategy. Pfizer’s strategic direction is further guided by a high-profile Board of Directors featuring former FDA Commissioner Dr. Scott Gottlieb and Lead Independent Director Shantanu Narayen (CEO of Adobe). The company’s capital structure is characterized by heavy institutional ownership, with The Vanguard Group, BlackRock, and State Street Corporation serving as its largest shareholders, reflecting its status as a foundational component of the global healthcare investment landscape.